ecancermedicalscience

Case Report

Quick and sustained clinical response to MEK inhibitor I in a NF1 patient with neurofibromas

28 Aug 2018
Honoré Papalia, Frédérique Audic, Gabriel Revon Rivière, Arnauld Verschuur, Nicolas André

Neurofibromatosis 1 (NF1) is an autosomal dominant tumour predisposition disorder with a birth incidence of about 1 in 2,700 and prevalence of 1 in 4,560. The NF1 gene codes for an ubiquitous protein: neurofibromin. Neurofibromin interacts with the proto-oncogene RAS to suppress tumour formation. Individuals with germline inactivation of the NF1 gene have a propensity to develop both benign and malignant tumours.

We report the case of a 12-year-old child with NF1, diagnosed at the age of 15 months, for whom the clinical course has been marked by the appearance of multiple cutaneous and paraspinal neurofibromas responsible for impaired walking, motor deficiency and pain. A treatment with an MEK inhibitor, trametinib, was initiated and led to a quick and sustained clinical response.

Related Articles

Deevyashali Parekh, Ansy H Patel, Areeb Khan, Eloho Olojakpoke, Ashay Karpe, Zoya Peelay, Vijay Patil
Tooba Ali, Laraib Khan, Bilal Mazhar Qureshi, Asim Hafiz, Maria Tariq, Khurram Minhas, Nasir Ali, Ahmed Nadeem Abbasi
Solomon Kibudde, Awusi Kavuma, Bonny Abal, Moses Fredrick Katumba, Cissy Bangidde Namutale, Daniel Kanyike, Israel Luutu
Swasthik Upadhya, Sameer Rastogi, Adarsh Barwad, Shamim Ahmed Shamim, Dikhra Khan, Sudheer Arava, Vineeta Ojha, Akshit Kumar Ganesan Karthikeyan, Akshya Kumar Bisoi
Hani Shihadeh, Ahmad Yousef, Ahmad Al-Leimon, Hussein Abu-Rumman, Laith Kreshan
Motunrayo Oluwabukola Adekunle, Aisha Musa, Chioma Ginika, Chisom Nri-Ezedii, Uduak Offiong, Hauwa Yusuf, Peter Odion Ubuane, Adewunmi Oyesakin, Ijeoma Nnenna Diaku-Akinwumi, Adaorah Onyiaorah